The Wave You Already Know Is Coming
You have read the GLP-1 headlines. You know Lilly and Novo are the entire conversation. You know Wegovy and Mounjaro reshaped the obesity category. You know your CFO has asked you three times this quarter whether your portfolio has any GLP-1 exposure.
Here is the part nobody is writing about.
There are twenty-three new anti-obesity drugs projected to receive approval across major markets by 2031. Oral GLP-1 therapies for obesity entered the market in late 2025. Five metabolic disease drugs are projected to pull in more than one hundred billion dollars combined by 2030. The obesity category alone is on track to become the largest single therapeutic area in pharma history.
And the field force model that pharma uses to launch and grow these brands has not changed in thirty years.
A pharma sales force of one thousand reps can effectively cover the prescriber universe for one major launch at a time. Maybe two if the launches are sequenced six months apart and the therapeutic areas are adjacent enough to share talk tracks. A second concurrent launch eats roughly forty percent of the first launch's call frequency. A third concurrent launch in the same TA breaks the model.
Twenty-three launches in the same therapeutic area in six years is not a model problem. It is a math problem.
The Math Most Commercial Teams Are Avoiding
Walk through it slowly.
Each new launch needs roughly thirty face-to-face contacts per high-decile prescriber in the first year. That is the empirical minimum to seat a new mechanism, surface a new safety profile, defend against the incumbent, and clear the formulary hurdle. Drop below thirty contacts, the share number flattens at six months and never recovers.
Your sales force has bandwidth for roughly two hundred and forty face-to-face contacts per rep per year, give or take, depending on territory geography and prescriber density. That includes existing brand maintenance, in-services, samples, and follow-up.
A rep carrying one launch and three established brands has about sixty to eighty contacts a year to allocate to the launch. Enough to barely cover a Tier 1 prescriber. Not enough to cover Tier 2.
Now layer twenty-three concurrent or near-concurrent launches in obesity across the next six years. Twenty-three brands competing for the same thirty contacts at the same prescribers. The math does not work even if every rep stops servicing every other product in their bag, which obviously cannot happen.
The result is not "we will be a little stretched." The result is that for every brand outside the top three by share-of-voice, the commercial model is structurally broken before launch day. You will write the launch deck. You will hire the reps. You will buy the conferences. And the prescribers will not have heard your brand name by the end of year one.
This is not a future problem. This is a 2026 to 2031 problem. The first wave of overlapping launches is already in regulatory review.
What the Top Three Are Doing About It
Lilly and Novo are not waiting. They are already deploying AI specifically to identify GLP-1-eligible patients, map their treatment journeys, and route prescriber education to the right HCPs at the right moments. Veradigm and other commercial AI platforms now offer GLP-1-specific patient journey analytics as a product line.
The translation: the market leaders are using AI to compress the rep-to-prescriber relationship into a smaller, more targeted set of conversations, and using digital channels to fill the gap on everything else. They are spending less per prescriber and reaching more of them, because the AI layer absorbs the work that used to require a physical visit.
Most other pharmas in the obesity race are still operating on the assumption that the field force, sized correctly and trained well, can cover the launch. That assumption is wrong. It has been wrong since 2024. It will be catastrophically wrong by 2027 when four of the twenty-three drugs are launching simultaneously.
What the Other Twenty Have to Do
If you are not Lilly or Novo, and you are launching an obesity asset between now and 2031, three things have to be true on launch day or you do not get share.
First, you have built a digital prescriber engagement layer that scales independently of headcount. Not "rep email follow-up." A standing engagement channel that delivers MLR-approved education, answers prescriber questions in compliant turn-by-turn dialogue, and surfaces the right clinical evidence at the right moment based on what that prescriber has actually asked about, prescribed, or read. This is the workflow that mid-pharma underbuilds the most.
Second, you have AI-powered prescriber identification that ranks targets not by call panel decile but by predicted response to your specific brand's mechanism, safety profile, and patient phenotype. Static segmentation built in 2023 will not survive a 2027 launch landscape where five competing GLP-1 and adjacent mechanisms are fighting for the same Tier 1 endocrinologists. You need targeting that recalibrates weekly against actual prescribing signals.
Third, you have measurable, audited adverse event capture that survives the post-launch PV surge. The obesity category is going to generate AE volume that pharma has not seen since the early statin era. The companies that capture AEs cleanly, route them to PV in minutes, and demonstrate compliance on inspection will preserve their label. The ones that try to do it manually across twenty-three concurrent launches will not.
These three workflows have a name. They are the same three I have been building inside KASFAM for the last eighteen months.
The Real Bottleneck Is Not AI. It Is Decision Speed.
The technology to do this is mature. The vendors exist. The case studies exist, including inside Lilly's and Novo's own commercial functions. The architecture is publicly documented.
The bottleneck is decision speed inside mid-tier pharma commercial organizations.
A decision to deploy an AI prescriber engagement layer typically takes a mid-pharma commercial team between fourteen and twenty-two months from "let's look into this" to first live deployment. Vendor selection alone runs six to nine months. Procurement adds three. Compliance adds three. IT integration adds six. Change management adds three.
The first overlapping obesity launches are inside that timeline. The second wave is inside half of it.
If you start the vendor selection process for AI prescriber engagement in mid-2026, you will be live in late 2027. Your competitor's brand has been in the market for fifteen months by then. The Tier 1 endocrinologist has already chosen.
The companies that are going to take share in this wave have already started, or are starting this quarter. The companies that wait until 2027 to start are not buying capability. They are buying a clean-up project.
The Consulting Engagement
My GLP-1 commercial readiness engagement is a six-week sprint, not a sixteen-week one, because the timeline does not allow for sixteen weeks.
Weeks 1-2: Launch landscape mapping.
We map your specific asset, its mechanism, safety profile, target population, and competitive cohort, against the projected 2026-2031 launch sequence. Where you launch into a quiet quarter versus a four-launch quarter. Where the share-of-voice math actually works versus where it structurally cannot. Which Tier 1 prescriber pool is realistically reachable through human reps and which is not.
Weeks 3-4: Field force and digital layer architecture.
We design the specific split between human rep coverage and digital prescriber engagement, by tier, by geography, by HCP behavior pattern. Which segment gets reps at thirty contacts a year. Which segment gets an AI-powered engagement layer at unlimited touch frequency. The economics of each split, including launch year one, two, and three.
Weeks 5-6: Build and integrate the engagement layer.
The AI prescriber engagement layer is deployed against your MLR-approved content library, integrated with your CRM and PV intake, and turned on for a pilot cohort of two to three hundred prescribers. Measurement is set up baseline-to-pilot for engagement rate, content delivery completion, prescriber question resolution, and downstream prescribing signal.
What You Get
A launch landscape map showing where your asset sits in the 2026-2031 wave and where the share-of-voice math is structurally feasible. A documented hybrid field force and digital engagement architecture, including the headcount math for each scenario. A live AI prescriber engagement layer covering the segment your reps cannot reach, integrated with your existing CRM and PV systems. A measured pilot performance report you can show the board.
Architectural performance envelope:
- Reachable prescriber universe expanded by 200-400 percent without growing field force headcount
- Per-prescriber engagement cost reduced by 60-80 percent on the digital-served segment
- AE capture compliance hardened against the post-launch volume surge
- Decision-to-deployment timeline compressed from 18 months to 6 weeks
How to Start
If you have a GLP-1, obesity, metabolic, or adjacent asset launching between now and 2031, the first decision is not whether to build this. The first decision is whether you start in Q3 of 2026 or Q1 of 2027.
The companies that start in Q3 will be live for the first major overlapping launch quarter. The companies that wait will be writing post-mortem decks.
I built a GLP-1 Launch Readiness Scorecard, one page, ten questions, that diagnoses where your specific launch sits today across field force capacity, digital engagement maturity, targeting precision, and PV readiness.
Comment "WAVE" on the LinkedIn post for this article and I will DM you the scorecard.
It takes ten minutes. It tells you whether the next launch is structurally on track or structurally underwater. It is the conversation I would want before walking into a board meeting in this category.
